Prostate Cancer Coverage from Every Angle

Recent News

Quality Care 2019: End-of-Life Use of Hormonal Agents in Patients With Prostate Cancer
How Does HIV Infection Affect Survival in Patients With Prostate Cancer?
FDA Accepts New Drug Application for Enzalutamide in Metastatic Hormone-Sensitive Prostate Cancer
FDA Safety Update on Risk of Prostate Cancer and Treatment for Parkinson’s Disease
Is Body Fat Associated With Risk of Aggressive Prostate Cancer?
Epigenetic Regulator in Double-Negative Prostate Cancer
Darolutamide Approved by the FDA for Non-Metastatic Castration-Resistant Prostate Cancer
Potential Predictive Biomarkers for PSMA-Targeted Therapies in Prostate Cancer
De-escalation of Bone-Targeting Agents for Bone Metastases From Prostate Cancer
Androgen-Deprivation Therapy and Risk of Dementia in Men With Prostate Cancer
Comparing Biopsy Methods in Detecting Prostate Cancer
Targeted Radionuclide Therapy for Metastatic Castration-Resistant Prostate Cancer
Initiative to Reduce Narcotic Prescribing in Robotic Radical Prostatectomy
Interim Scan During Radioligand Therapy for Men With Advanced Prostate Cancer
ASCO 2019: TOPARP-B Trial of Olaparib in Castration-Resistant Prostate Cancer
ASCO 2019: Comparing First-Line Treatments in Poor-Prognosis Metastatic Prostate Cancer
ASCO 2019: Adding Apalutamide to Androgen-Deprivation Therapy in Prostate Cancer
ASCO 2019: Does Adding Abiraterone Acetate to Enzalutamide Improve Outcomes in Metastatic Prostate Cancer?
ASCO 2019: Quality-of-Life Outcomes With Darolutamide in Prostate Cancer
FDA Grants Fast Track Designation to ARV-110 in Metastatic Castration-Resistant Prostate Cancer
New Prognostic Marker Under Study in Metastatic Prostate Cancer
ASCO 2019: Overall Survival With or Without Enzalutamide for Prostate Cancer
Which Genomic Alterations Are Linked to Poor Outcomes in Advanced Prostate Cancer?
AUA 2019: Androgen-Deprivation Therapy and Risk to Cognitive Health
AUA 2019: Can a Beta-Blocker Impact the Risk of Prostate Cancer?
AUA 2019: Targeted Versus Systemic Biopsy for Diagnosing Prostate Cancer
ESTRO 2019: High-Dose-Rate Monotherapy for Localized Prostate Cancer
Darolutamide Granted NDA and Priority Review in Nonmetastatic Castration-Resistant Prostate Cancer
Predicting Adverse Prostate Cancer Pathology With Genetic Assay
Prostate Cancer’s Genetic Relationship to Other Cancers
Novel Antibody-Drug Conjugate in Castration-Resistant Prostate Cancer
Should Docetaxel Be Added to ADT in High-Risk Prostate Cancer?
Tumor-Lysis Syndrome in Patients With Genitourinary Cancers
Does Sipuleucel-T Improve Survival in African Americans With Advanced Prostate Cancer?
EAU Congress 2019: Compounds Found in Coffee May Inhibit Growth of Prostate Cancer Cells

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.